MX2017010389A - Proteasa de cisteina. - Google Patents

Proteasa de cisteina.

Info

Publication number
MX2017010389A
MX2017010389A MX2017010389A MX2017010389A MX2017010389A MX 2017010389 A MX2017010389 A MX 2017010389A MX 2017010389 A MX2017010389 A MX 2017010389A MX 2017010389 A MX2017010389 A MX 2017010389A MX 2017010389 A MX2017010389 A MX 2017010389A
Authority
MX
Mexico
Prior art keywords
cysteine protease
igg
vivo
methods
polypeptide
Prior art date
Application number
MX2017010389A
Other languages
English (en)
Inventor
JARNUM Sofia
Kjellman Christian
Nordahl Emma
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of MX2017010389A publication Critical patent/MX2017010389A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • C12N9/6475Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • C12Y304/2201Streptopain (3.4.22.10)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a un polipéptido novedoso que exhibe actividad de proteasa de cisteína de IgG y usos in vivo y ex vivo de los mismos. Usos del polipéptido incluyen métodos para la prevención o tratamiento de enfermedades y afecciones mediadas por IgG, y métodos para el análisis de IgG.
MX2017010389A 2015-02-12 2016-02-12 Proteasa de cisteina. MX2017010389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502305A GB201502305D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053054 WO2016128559A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (1)

Publication Number Publication Date
MX2017010389A true MX2017010389A (es) 2017-12-07

Family

ID=52781455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010389A MX2017010389A (es) 2015-02-12 2016-02-12 Proteasa de cisteina.

Country Status (28)

Country Link
US (3) US10758597B2 (es)
EP (2) EP4265719A1 (es)
JP (1) JP6879921B2 (es)
KR (1) KR102524594B1 (es)
CN (2) CN113564150A (es)
AU (1) AU2016217801B2 (es)
BR (1) BR112017017286A2 (es)
CA (1) CA2976016C (es)
CL (1) CL2017002066A1 (es)
CO (1) CO2017009060A2 (es)
DK (1) DK3256579T3 (es)
EA (1) EA035896B1 (es)
ES (1) ES2962794T3 (es)
FI (1) FI3256579T3 (es)
GB (1) GB201502305D0 (es)
HR (1) HRP20231496T1 (es)
HU (1) HUE064122T2 (es)
IL (1) IL253939B (es)
LT (1) LT3256579T (es)
MX (1) MX2017010389A (es)
MY (1) MY187486A (es)
PL (1) PL3256579T3 (es)
PT (1) PT3256579T (es)
RS (1) RS64840B1 (es)
SG (1) SG11201706349YA (es)
SI (1) SI3256579T1 (es)
WO (1) WO2016128559A1 (es)
ZA (1) ZA201705114B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108410798A (zh) * 2018-03-27 2018-08-17 福建三造血技术有限公司 细胞分离用微珠洗脱液及配制方法
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US20220143213A1 (en) * 2019-01-28 2022-05-12 Duke University Composition and Methods for Evading Humoral Immunity
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
CA3172625A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
EP4093436A4 (en) * 2020-01-22 2024-03-27 Spark Therapeutics Inc COMPOSITIONS AND METHODS FOR INCREASE OR IMPROVE TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVAL OR DECREASE IMMUNOGLOBULINS
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
JP2023514204A (ja) 2020-02-14 2023-04-05 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Cdkl5欠損障害を処置するための遺伝子治療
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
JP2023529186A (ja) 2020-06-05 2023-07-07 上海宝済薬業有限公司 酵素とウィルスとの薬物組成物及びその使用
CN115515631A (zh) * 2020-09-21 2022-12-23 上海宝济药业有限公司 一种药物组合及其应用
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 肢帯型2i(lgmd2i)を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質(fkrp)の治療的アデノ随伴ウイルス送達
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル, インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
FR3125965A1 (fr) * 2021-08-05 2023-02-10 Mc Saf Conjugués anticorps-médicament
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
CA3237815A1 (en) 2021-11-15 2023-05-19 Raghuveer RANGANATHAN Methods for enhancing adoptive cell transfer immunotherapies
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA2421278A1 (en) * 1998-03-11 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
ES2307564T3 (es) 2000-12-21 2008-12-01 Id Biomedical Corporation Antigenos de streptococcus pyrogenes y fragmentos de adn correspondientes.
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
JP5427409B2 (ja) * 2005-06-09 2014-02-26 ハンサ メディカル アクチボラゲット 自己免疫疾患及び移植片拒絶反応を治療するためのIdeSプロテイナーゼ(化膿連鎖球菌由来)の使用
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
CN101889082A (zh) 2007-09-14 2010-11-17 季诺维斯公司 用于解离Fcgamma-受体-IgG复合物以及纯化与检测IgG的方法和试剂盒
WO2009075646A1 (en) 2007-12-13 2009-06-18 Bengt Guss Improved immunizing composition
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
ES2535963T3 (es) 2009-02-09 2015-05-19 Roche Glycart Ag Análisis del patrón de glicosilación de inmunoglobulina
CA2799136A1 (en) * 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
ES2962794T3 (es) 2024-03-21
HRP20231496T1 (hr) 2024-03-01
US20180037962A1 (en) 2018-02-08
IL253939B (en) 2020-01-30
BR112017017286A2 (pt) 2018-04-17
CL2017002066A1 (es) 2018-02-02
CN107532158A (zh) 2018-01-02
SG11201706349YA (en) 2017-09-28
US10758597B2 (en) 2020-09-01
KR20170110153A (ko) 2017-10-10
MY187486A (en) 2021-09-24
LT3256579T (lt) 2023-11-27
CA2976016C (en) 2023-08-29
CO2017009060A2 (es) 2018-01-16
EP3256579A1 (en) 2017-12-20
EA201791775A1 (ru) 2018-02-28
FI3256579T3 (fi) 2023-11-13
EP3256579B1 (en) 2023-08-30
AU2016217801A1 (en) 2017-08-10
HUE064122T2 (hu) 2024-03-28
GB201502305D0 (en) 2015-04-01
AU2016217801B2 (en) 2022-03-17
EP4265719A1 (en) 2023-10-25
KR102524594B1 (ko) 2023-04-21
ZA201705114B (en) 2024-01-31
SI3256579T1 (sl) 2024-01-31
US11524057B2 (en) 2022-12-13
US20230302100A1 (en) 2023-09-28
PL3256579T3 (pl) 2024-02-26
WO2016128559A1 (en) 2016-08-18
CA2976016A1 (en) 2016-08-18
JP6879921B2 (ja) 2021-06-02
DK3256579T3 (en) 2023-11-20
CN113564150A (zh) 2021-10-29
EA035896B1 (ru) 2020-08-27
PT3256579T (pt) 2023-11-23
JP2018510622A (ja) 2018-04-19
RS64840B1 (sr) 2023-12-29
US20200179497A1 (en) 2020-06-11
IL253939A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
ZA201705114B (en) Cysteine protease
ZA201705113B (en) Cysteine protease
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
PH12018500578A1 (en) Methods of treating inflammatory diseases
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2022005888A (es) Metodos para tratar afecciones oculares.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
MX2017006692A (es) Trastornos neurodegenerativos.
MX2017013601A (es) Un proceso de etapas multiples para la produccion de no.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis